Phenotypic spectrum of cardiac conduction disturbance and cardiomyopathy linked to titin canonical splice-site variants

1:1
Canonical splice-site TTN variants (TTNcsv) are linked to cardiac conduction disturbances, producing mostly non-truncating transcripts, unlike DCM-associated TTNcsv. These findings highlight variant-specific transcriptional effects and their potential role in cardiac phenotypes.
Aims

Truncating variations in the titin gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) and have been implicated in various arrhythmic and heart failure phenotypes. Nonetheless, predicting the pathogenicity of a distinct subtype of TTNtv, canonical splice-site variations (TTNcsv), remains challenging. Furthermore, the precise transcriptional and phenotypic consequences associated with TTNcsv remain unclear. We evaluated the transcriptional profiles of TTN in vitro, focusing on TTNcsv found in patients with cardiac dysfunction, and compared them with their phenotypic manifestations.

Methods and results

Genome-wide linkage analysis, whole-exome sequencing, and whole-genome sequencing were performed on a five-generation family with cardiac conduction disturbance (CCD). In addition, whole-genome sequencing was performed on 402 Japanese biobank patients with cardiomyopathy (CM) or unidentified cardiac dysfunction. Transcriptional profiles of TTNcsv were evaluated by RNA-Seq of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and endomyocardial biopsy specimens, and by minigene assays. A rare segregating TTNcsv (c.49049-2A>C) was identified in the five-generation family with CCD. RNA-Seq and minigene assays revealed complex aberrant TTN splicing transcripts: predominantly non-truncating transcripts caused by an 18 bp in-frame deletion (83–90%) and minor truncating transcripts (10–17%). Two additional TTNcsv were identified in biobank participants by whole-genome sequencing. A minigene assay of TTNcsv c.67348+1G>A, identified in a CCD patient with mild cardiac dysfunction, revealed predominantly non-truncating transcripts (95%), caused by retention of a 90 bp in-frame intron, along with 5% truncating TTN transcripts, caused by a 50 bp frameshift deletion, mirroring the TTNcsv observed in the familial CCD. In contrast, the DCM-associated TTNcsv c.67637-2A>G generated 87% truncating TTN transcripts, attributed to frameshift intron retention and cryptic splicing.

Conclusion

The clinical data from this family suggest a close association between TTNcsv and CCD, which may involve an increase in non-truncating transcripts. Further studies are required to determine their precise relationship and the underlying mechanisms.

Year of publication

2025

Source

Cardiovascular Research, Volume 121, Issue 11, September 2025, Pages 1712–1721

Author

Taisuke Ishikawa , Hiroki Kimoto , Akiko Seki , Manabu Shirai , Kenta Uto , Takeru Makiyama , Takeshi Kitai , Hiroyuki Mishima , Daniel Trujillano , Floriane Simonet , Estelle Baron , Pierre Lindenbaum , Florence Kyndt , Adeline Goudal , Norihide Fukushima , Tomoyuki Fujita , Kinta Hatakeyama , Nobuhisa Hagiwara , Koh-ichiro Yoshiura , Richard Redon , Christian Dina , Xavier Estivill , Stephan Ossowski , Mathieu Courtheix , Vincent Probst , Julien Barc , Jean-Jacques Schott , Naomasa Makita

You might also be interested in

The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.
At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
June 7 - June 10
The Open Academy x ERDERA accompanies patient advocates by offering rare-disease specific comprehensive training programmes that empower advocates with the knowledge, skills and confidence they need to engage with different stakeholders as equal partners.